Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Adipose-derived stem cell exosomes: multifaceted therapeutic applications in regenerative medicine.

Rau CS., Kuo PJ., Hsieh CH.

Clinical Trial on Cardiovascular Disease, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Int J Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Surg (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40696930
PMCID
PMC12527763
DOI
10.1097/JS9.0000000000002841
NCT
NCT04276941
Citations
7

Abstract (original English)

Adipose-derived stem cell exosomes (ADSC-Exos) have emerged as promising cell-free therapeutic agents in regenerative medicine, offering many benefits of stem cell therapy without the risks of cell transplantation. These nanoscale vesicles (30-150 nm) contain bioactive cargo including proteins, microRNAs, and lipids that mediate tissue repair through multiple mechanisms: promoting angiogenesis, modulating inflammation, reducing fibrosis, and activating endogenous regenerative pathways. Recent preclinical studies demonstrate remarkable efficacy across diverse applications, from accelerating chronic wound healing and stimulating skin regeneration to repairing cartilage, bone, and nerve tissues. In cardiovascular applications, ADSC-Exos protect against ischemic damage and improve cardiac function post-infarction. Neurologically, they show potential in stroke recovery, spinal cord injury, and neurodegenerative diseases by crossing the blood-brain barrier and delivering neuroprotective signals. Their potent immunomodulatory properties make them candidates for treating inflammatory and autoimmune conditions. Early clinical trials report encouraging safety profiles and preliminary efficacy in conditions ranging from acne scarring to Alzheimer's disease. However, significant challenges remain in standardizing isolation methods, ensuring consistent potency, scaling production to clinica

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansExosomesRegenerative MedicineAdipose TissueAnimalsStem Cell TransplantationStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research